theophylline 300 MG Extended Release Oral Capsule [Theo-24]
theophylline
RxCUI: 844591
What the CMS Formulary Data Shows for theophylline 300 MG Extended Release Oral Capsule [Theo-24]
Per the CMS 2026 Part D formulary file, theophylline 300 MG Extended Release Oral Capsule [Theo-24] (RxNorm concept RXCUI 844591, generic name theophylline) appears on 27 distinct formulary files spanning 693 Medicare Part D plan offerings - 13.7% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 3.4.
Real-world access to theophylline 300 MG Extended Release Oral Capsule [Theo-24] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 39,063 Part D beneficiaries filled theophylline 300 MG Extended Release Oral Capsule [Theo-24] in 2023, with total plan-and-beneficiary spending of $24,909,786 and an average per-beneficiary annual cost of $637.68. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry theophylline 300 MG Extended Release Oral Capsule [Theo-24] today.
Coverage Details
- Formularies covering
- 27
- Plans covering
- 693
- Coverage rate
- 13.7%
- Tier range
- Tier 1 – Tier 4
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 39,063
- Total spending
- $24,909,786
- Avg per beneficiary
- $637.68
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering theophylline 300 MG Extended Release Oral Capsule [Theo-24]
100 Medicare Advantage plans with Part D drug coverage include this drug.
Frequently Asked Questions
Is theophylline 300 MG Extended Release Oral Capsule [Theo-24] covered by Medicare Part D?
Yes, theophylline 300 MG Extended Release Oral Capsule [Theo-24] is covered by 693 Medicare Part D plans (13.7% of all Part D formularies).
What tier is theophylline 300 MG Extended Release Oral Capsule [Theo-24] on Medicare Part D plans?
theophylline 300 MG Extended Release Oral Capsule [Theo-24] averages Tier 3.4 across Part D plans, ranging from Tier 1 to Tier 4.
Does theophylline 300 MG Extended Release Oral Capsule [Theo-24] require prior authorization?
0% of Part D formularies require prior authorization for theophylline 300 MG Extended Release Oral Capsule [Theo-24]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on theophylline 300 MG Extended Release Oral Capsule [Theo-24]?
In 2023, total Medicare Part D spending on theophylline 300 MG Extended Release Oral Capsule [Theo-24] was $24,909,786, covering 39,063 beneficiaries. The average spend per beneficiary was $637.68.
Read our methodology - how this data is sourced, computed, and verified.